ReviewThe American journal of pathology2013
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Review in The American journal of pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 105 citations in OpenAlex.
- Pathobiology and clinical significance of malignant pleural effusions.EMBO molecular medicine · 2026Review
- Time till pleuropulmonary recurrence for mesothelioma and high grade appendiceal neoplasm after CRS/HIPEC.Pleura and peritoneum · 2025Article
- Functional Characterization of the Hephaestin Variant D568H Provides Novel Mechanistic Insights on Iron-Dependent Asbestos-Induced Carcinogenesis.International journal of molecular sciences · 2025Article
- Cellular defense mechanisms against asbestos fibers.Frontiers in public health · 2025Review
- ECM Mechanoregulation in Malignant Pleural Mesothelioma.Frontiers in bioengineering and biotechnology · 2022Article
- Review
- Histological comparison of malignant epithelioid mesothelioma in young and adult cattle.The Journal of veterinary medical science · 2021Article
- C1q-HA Matrix Regulates the Local Synthesis of Hyaluronan in Malignant Pleural Mesothelioma by Modulating HAS3 Expression.Cancers · 2021Article
- Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma.Frontiers in oncology · 2020Article
- Targeting Calcium Signalling in Malignant Mesothelioma.Cancers · 2019Review
- Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma.FASEB bioAdvances · 2019Article
- Exosomal miR-16-5p as a target for malignant mesothelioma.Scientific reports · 2019Article
- Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.Translational oncology · 2019Article
- CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.BMC cancer · 2019Article
- Impact of asbestos on public health: a retrospective study on a series of subjects with occupational and non-occupational exposure to asbestos during the activity of Fibronit plant (Broni, Italy).Journal of public health research · 2018Article
- Article
- Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.Scientific reports · 2018Article
- Article
- Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.International journal of molecular sciences · 2018Review
- Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Malignant mesothelioma (MM) is a relatively rare but devastating tumor that is increasing worldwide. Yet, because of difficulties in early diagnosis and resistance to conventional therapies, MM remains a challenge for pathologists and clinicians to treat. In recent years, much has been revealed regarding the mechanisms of interactions of pathogenic fibers with mesothelial cells, crucial signaling pathways, and genetic and epigenetic events that may occur during the pathogenesis of these unusual, pleiomorphic tumors. These observations support a scenario whereby mesothelial cells undergo a series of chronic injury, inflammation, and proliferation in the long latency period of MM development that may be perpetuated by durable fibers, the tumor microenvironment, and inflammatory stimuli. One culprit in sustained inflammation is the activated inflammasome, a component of macrophages or mesothelial cells that leads to production of chemotactic, growth-promoting, and angiogenic cytokines. This information has been vital to designing novel therapeutic approaches for patients with MM that focus on immunotherapy, targeting growth factor receptors and pathways, overcoming resistance to apoptosis, and modifying epigenetic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.